In response to the current COVID-19 pandemic, the ANCHOR study team has advised local site staff to contact ANCHOR participants who are scheduled to be seen in the next 4 weeks about whether they should come in for their appointment. If you do not hear from your site’s study staff, please reach out to them. If you are waiting to be screened for the ANCHOR study, please be patient- we WILL see you as soon as we possibly can, once it is safe to do so. In the meantime, please contact your local ANCHOR site if you have any questions or concerns.
Jeff Taylor is a 25+ year survivor of AIDS and cancer, and has been active in HIV research advocacy since enrolling in the ACTG's first AZT trials in the late 80's. He served for five years on the ACTG's Community Constituency Group (now CSS--where he was the community liaison to the Complications Research Agenda Committee (now OpMan), and was on the ACTG's original metabolics focus group formed to study emerging lipodystrophy. Currently, he continues to serve on the UCSD AntiViral Research Center's Community Advisory Board, the NCI's AIDS Malignancy Consortium as a community representative, DHHS AntiRetroviral Guidelines Panel, and on the Program Committee for CROI. He also serves on the AIDS Treatment Activists Coalition's Drug Development Committee--which meets regularly with pharma and FDA on HIV drug development issues. Locally, Jeff produces a monthly treatment education series on HIV treatment issues for HIV patients & providers, serves on the regional Ryan White Planning Council, and co-chairs the Client Advocacy Committee of the Desert AIDS Project.